ELVN Earnings Enliven Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–21 of 21
| Q2 2026 | 2026-06-30 | -0.87 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.38 | 2026-05-07 | 10-Q |
| FY 2025 | 2025-12-31 | -1.83 | 2026-03-03 | 10-K |
| Q3 2025 | 2025-09-30 | -1.35 | 2025-11-12 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.05 | 2026-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.57 | 2026-05-07 | 10-Q |
| FY 2025 | 2024-12-31 | -1.89 | 2026-03-03 | 10-K |
| Q3 2025 | 2024-09-30 | -1.43 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.95 | 2025-08-13 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.54 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -2.01 | 2025-03-13 | 10-K |
| Q3 2024 | 2023-09-30 | -1.55 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.05 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.80 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -12.05 | 2024-03-14 | 10-K |
| Q3 2023 | 2022-09-30 | -9.15 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -5.87 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -3.01 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -2.37 | 2023-02-10 | 10-K |
| Q3 2022 | 2021-09-30 | -1.33 | 2022-10-25 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.33 | 2022-08-03 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.